June 12, 2020 / 8:23 PM / 24 days ago

BRIEF-Roche Announces 2-Year Risdiplam Data From Sunfish

June 12 (Reuters) - Roche Holding AG:

* ROCHE ANNOUNCES 2-YEAR RISDIPLAM DATA FROM SUNFISH AND NEW DATA FROM JEWELFISH IN INFANTS, CHILDREN AND ADULTS WITH SPINAL MUSCULAR ATROPHY (SMA)

* ROCHE - SUNFISH PART 1 SHOWED RISDIPLAM SIGNIFICANTLY IMPROVED MOTOR FUNCTION AFTER 24 MTHS TREATMENT IN PEOPLE AGED 2-25 YRS WITH TYPES 2 OR 3 SMA

* JEWELFISH STUDY PRELIMINARY 12 MONTH DATA IN PREVIOUSLY TREATED PATIENTS SHOWED RAPID AND SUSTAINED INCREASES IN SMN PROTEIN LEVELS

* SAFETY IN SUNFISH AND JEWELFISH WAS CONSISTENT WITH SAFETY PROFILE OBSERVED TO DATE AND NO NEW SAFETY SIGNALS WERE IDENTIFIED

* EXPLORATORY EFFICACY ANALYSIS OF PART 1 OF SUNFISH STUDY ASSESSED MOTOR FUNCTION, USING MOTOR FUNCTION MEASURE (MFM) SCALE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below